Spatial Segregation of Roma Settlements Within Serbian Cities. Examples from Belgrade, Novi Sad, and Kruševac

This chapter focuses on the spatial segregation of Roma settlements within Serbian cities, shaped by the long-standing ethnic distance and social exclusion. In order to understand the broader context, the historical background against which Roma settlements emerged in Serbia, as well as their current demographic, legislative, and urban characteristics, are briefly presented. Several forms of segregation of Roma settlements are analysed, including segregation as a consequence of racist hostility, institutional discrimination by city administration, and development-based conflicts. Examples of setting up a wall enclosing a Roma settlement in Kruševac, racist pressures that prevent the construction of housing for Roma in Belgrade and the reluctance to improve and legalise Roma settlements in Novi Sad, illustrate the various manifestations of segregation and division of urban space in Serbia.The Urban Book Serie

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies

Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors

The aim of this study was to determine the plasma selenium (Se), copper (Cu), and zinc (Zn) levels and to evaluate their possible association with metabolic syndrome (MetS) components in patients with schizophrenia. The study group consisted of 60 patients with schizophrenia and 60 sex- and age-matched healthy controls. Anthropometric measurements, blood pressure, and biochemical analysis of fasting blood were performed in all subjects. Patients with schizophrenia had significantly higher plasma Cu concentrations compared with controls (0.97 +/- 0.31 vs. 0.77 +/- 0.32 mg/L, p = 0.001). The plasma Cu concentration showed a positive correlation with plasma glucose and diastolic blood pressure in the patient groups (r (s) = 0.263, p lt 0.05 and r (s) = 0.272, p lt 0.05, respectively). The plasma Se level correlated positive with MetS score (r (s) = 0.385, p lt 0.01), waist circumference (r (s) = 0.344, p lt 0.05), plasma glucose (r (s) = 0.319, p lt 0.05), and triglyceride concentrations (r (s) = 0.462, p lt 0.001) in patients with schizophrenia. Plasma Zn did not correlate with any of the MetS components. These results suggest that alterations in plasma Cu and Se levels in medicated patients with schizophrenia could be associated with metabolic risk factors